PL1626973T3 - (1S,5S)-3-(5,6-dichloro-3-pirydynylo)-3,6-diazabicyklo[3.2.0]heptan stanowiący skuteczny środek przeciwbólowy - Google Patents

(1S,5S)-3-(5,6-dichloro-3-pirydynylo)-3,6-diazabicyklo[3.2.0]heptan stanowiący skuteczny środek przeciwbólowy

Info

Publication number
PL1626973T3
PL1626973T3 PL04752844T PL04752844T PL1626973T3 PL 1626973 T3 PL1626973 T3 PL 1626973T3 PL 04752844 T PL04752844 T PL 04752844T PL 04752844 T PL04752844 T PL 04752844T PL 1626973 T3 PL1626973 T3 PL 1626973T3
Authority
PL
Poland
Prior art keywords
diazabicyclo
pyridinyl
dichloro
heptane
analgesic agent
Prior art date
Application number
PL04752844T
Other languages
English (en)
Inventor
Michael J Buckley
Jianguo Ji
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PL1626973T3 publication Critical patent/PL1626973T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL04752844T 2003-05-27 2004-05-20 (1S,5S)-3-(5,6-dichloro-3-pirydynylo)-3,6-diazabicyklo[3.2.0]heptan stanowiący skuteczny środek przeciwbólowy PL1626973T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/445,555 US20040242641A1 (en) 2003-05-27 2003-05-27 (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
PCT/US2004/015905 WO2004106342A1 (en) 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
EP04752844A EP1626973B1 (en) 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent

Publications (1)

Publication Number Publication Date
PL1626973T3 true PL1626973T3 (pl) 2011-04-29

Family

ID=33450880

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04752844T PL1626973T3 (pl) 2003-05-27 2004-05-20 (1S,5S)-3-(5,6-dichloro-3-pirydynylo)-3,6-diazabicyklo[3.2.0]heptan stanowiący skuteczny środek przeciwbólowy

Country Status (21)

Country Link
US (1) US20040242641A1 (pl)
EP (1) EP1626973B1 (pl)
JP (1) JP4716999B2 (pl)
KR (2) KR101238281B1 (pl)
CN (1) CN1826344B (pl)
AT (1) ATE485296T1 (pl)
AU (1) AU2004243270B2 (pl)
BR (1) BRPI0410808A (pl)
CA (1) CA2526530C (pl)
CY (1) CY1111946T1 (pl)
DE (1) DE602004029671D1 (pl)
DK (1) DK1626973T3 (pl)
ES (1) ES2352199T3 (pl)
MX (1) MXPA05012738A (pl)
NZ (2) NZ588123A (pl)
PL (1) PL1626973T3 (pl)
PT (1) PT1626973E (pl)
SI (1) SI1626973T1 (pl)
TW (1) TWI332502B (pl)
WO (1) WO2004106342A1 (pl)
ZA (1) ZA200509601B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7354937B2 (en) * 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8222278B2 (en) * 2008-06-03 2012-07-17 Abbott Laboratories Treatment of attention-deficit/hyperactivity disorder
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
EP2491034B1 (en) * 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2011090669A1 (en) * 2010-01-20 2011-07-28 Abbott Laboratories Methods for treating pain
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
EP1147112B1 (en) * 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
EP1175416B1 (en) * 1999-04-26 2003-07-16 Neurosearch A/S Heteroaryl diazacycloalkanes, their preparation and use
ES2226844T3 (es) * 1999-05-21 2005-04-01 Abbott Laboratories Aminoazaciclos heterociclicos sustituidos utiles como agentes activos sobre el sistema nervioso central.
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents

Also Published As

Publication number Publication date
CN1826344B (zh) 2013-03-06
BRPI0410808A (pt) 2006-06-27
JP2007500220A (ja) 2007-01-11
WO2004106342A1 (en) 2004-12-09
SI1626973T1 (sl) 2011-01-31
MXPA05012738A (es) 2006-02-22
NZ543615A (en) 2009-04-30
ATE485296T1 (de) 2010-11-15
US20040242641A1 (en) 2004-12-02
DK1626973T3 (da) 2011-01-10
CY1111946T1 (el) 2015-11-04
KR20060015738A (ko) 2006-02-20
EP1626973B1 (en) 2010-10-20
AU2004243270A1 (en) 2004-12-09
KR101238281B1 (ko) 2013-03-04
TW200510420A (en) 2005-03-16
CA2526530A1 (en) 2004-12-09
CA2526530C (en) 2013-01-08
KR20120014235A (ko) 2012-02-16
ZA200509601B (en) 2006-10-25
AU2004243270B2 (en) 2009-12-17
TWI332502B (en) 2010-11-01
EP1626973A1 (en) 2006-02-22
PT1626973E (pt) 2010-12-31
CN1826344A (zh) 2006-08-30
NZ588123A (en) 2012-04-27
ES2352199T3 (es) 2011-02-16
JP4716999B2 (ja) 2011-07-06
HK1092135A1 (en) 2007-02-02
DE602004029671D1 (de) 2010-12-02

Similar Documents

Publication Publication Date Title
CY1111946T1 (el) To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2003057837A3 (en) Methods for using anti-muc18 antibodies
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2003057838A3 (en) Antibodies against the muc18 antigen
WO2003057006A3 (en) Use of antibodies against the muc18 antigen
WO2005107726A3 (en) Method for the treatment of back pain
HK1038755A1 (zh) Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
PL346876A1 (en) Mglur5 antagonists for the treatment of pain and anxiety
MXPA05003104A (es) Hidromorfonas n-sustituidas y uso de las mismas.
IL180882A0 (en) (1s,5s)-3-(5,6-dichloropyridin-3-yl)-3-6-diazabicyclo[3.2.0]heptane benzenesulfonate
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
GB0111186D0 (en) Novel compounds
WO2002066500A3 (de) ANTAGONISTEN FÜR Α4β7-INTEGRIN
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
PT1463735E (pt) Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
TW200616631A (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane